Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 3:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 182 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Aspirin-Placebo Clear all
Completed Phase 4 Interventional Results available

Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

NCT02836652
View directory record Official record
Conditions
Heart Failure
Interventions
HeartMate II (HMII), Warfarin, acetylsalicylic acid (ASA) therapy
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
50 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2022 · Synced Sep 10, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Results available

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)

NCT00249873
View directory record Official record
Conditions
Atrial Fibrillation, Vascular Risk
Interventions
clopidogrel (SR25990C), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
7,554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2015 · Synced Sep 10, 2026, 3:34 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

In-Vivo Bleeding Volume Test for Platelet-Aspirin Interaction

NCT01047722
View directory record Official record
Conditions
Healthy
Interventions
Aspirin ingestion followed by doing a Bleeding Volume Test, Gatorade Placebo followed by Bleeding Volume Test.
Drug · Procedure
Lead sponsor
Klein, Jeffrey A., M.D.
Individual
Eligibility
18 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
2
States / cities
Newport Beach, California • San Juan Capistrano, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2015 · Synced Sep 10, 2026, 3:34 AM EDT
Terminated Phase 3 Interventional

Chemoprevention of Colorectal Adenomas

NCT00486512
View directory record Official record
Conditions
Adenomatous Polyps
Interventions
0.5 mg calcitriol (1a -25-dihydroxycholecalciferol), 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3), placebo to 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol), placebo to 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3), Colonoscopy
Drug · Procedure
Lead sponsor
Colotech A/S
Industry
Eligibility
40 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
24
States / cities
Huntsville, Alabama • San Diego, California • Clearwater, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 10, 2026, 3:34 AM EDT
Completed Phase 4 Interventional Results available

Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention

NCT02270242
View directory record Official record
Conditions
Cardiovascular Disease, Interventional Cardiology
Interventions
Aspirin, Placebo, ticagrelor
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
9,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Sep 10, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia

NCT00626392
View directory record Official record
Conditions
Dyslipidemia
Interventions
niacin extended-release (NER), aspirin (ASA), aspirin placebo (ASA Pbo)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
26
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2009 · Synced Sep 10, 2026, 3:34 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation

NCT02521285
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Adenocarcinoma
Interventions
Aspirin, Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 10, 2026, 3:34 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Aspirin in Patients With Vestibular Schwannoma

NCT03079999
View directory record Official record
Conditions
Vestibular Schwannoma, Acoustic Neuroma, Neurofibromatosis 2
Interventions
Aspirin, Placebo
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
12 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
5
States / cities
Stanford, California • Miami, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 10, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

NCT02504216
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Rivaroxaban-Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
6,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
105
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 10, 2026, 3:34 AM EDT
Completed Phase 1 Interventional

Treatment of Supine Hypertension in Autonomic Failure

NCT00223717
View directory record Official record
Conditions
Hypertension
Interventions
Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress
Drug · Dietary Supplement · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 10, 2026, 3:34 AM EDT
Terminated Phase 3 Interventional

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

NCT00557921
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
Drug
Lead sponsor
Cogentus Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
247
States / cities
Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2009 · Synced Sep 10, 2026, 3:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Thromboxane Function in Women With Endometriosis

NCT05962034
View directory record Official record
Conditions
Endometriosis
Interventions
Aspirin, Placebo
Drug · Other
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 10, 2026, 3:34 AM EDT
Completed Phase 4 Interventional Results available

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

NCT02415400
View directory record Official record
Conditions
Acute Coronary Syndromes
Interventions
Apixaban, vitamin K antagonist, Acetylsalicylic acid, Acetylsalicylic acid placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 95 Years
Enrollment
4,614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
143
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 10, 2026, 3:34 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

NUTRITION: Natural Tocotrienol Against Ischemic Stroke Event

NCT01578629
View directory record Official record
Conditions
Ischemic Stroke, Transient Ischemic Attack (TIA)
Interventions
Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin, Placebo vehicle control
Other
Lead sponsor
Andrew Slivka
Other
Eligibility
40 Years to 70 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2021 · Synced Sep 10, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

NCT01568112
View directory record Official record
Conditions
Healthy
Interventions
BG00012 (dimethyl fumarate), BG00012 placebo, ASA, ASA placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
25 Years to 55 Years
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2016 · Synced Sep 10, 2026, 3:34 AM EDT
Recruiting Not applicable Interventional

Impact of Biophoton Therapy on Chronic Severe Arthritis Pain

NCT06915012
View directory record Official record
Conditions
Arthritis
Interventions
Tesla BioHealing(R) Biophoton Generators
Device
Lead sponsor
First Institute of All Medicines
Other
Eligibility
18 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Butler, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 10, 2026, 3:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old

NCT04122170
View directory record Official record
Conditions
Healthy
Interventions
Ticagrelor Oral Tablet - Pre-Treatment, Aspirin (ASA) Oral Tablet - Pre-Treatment, Bentracimab (PB2452) Infusion, Placebo (0.9% Sodium chloride) infusion
Drug
Lead sponsor
SFJ Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
13
States / cities
Rogers, Arkansas • Cypress, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Sep 10, 2026, 3:34 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis

NCT02047539
View directory record Official record
Conditions
Clinical High Risk for Psychosis
Interventions
Aspirin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
19 Years to 35 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Sep 10, 2026, 3:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Anti-Platelets in Chronic Obstructive Pulmonary Disease

NCT05567562
View directory record Official record
Conditions
COPD, Emphysema, Emphysema or COPD
Interventions
dual anti-platelet therapy, Placebo
Combination Product · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 10, 2026, 3:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin

NCT01094483
View directory record Official record
Conditions
Platelet Inhibition
Interventions
PN400, ASA, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2010 · Synced Sep 10, 2026, 3:34 AM EDT
Not listed No phase listed Observational

Effects of Omega-3 Fatty Acids on Platelets in Patients With Coronary Artery Disease With Hypertriglyceridemia

NCT01086163
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Omacor, omega-3 fatty acids in CAD patients
Drug
Lead sponsor
HeartDrug Research LLC
Other
Eligibility
50 Years to 60 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2010 · Synced Sep 10, 2026, 3:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Aspirin in Gestation and Reproduction

NCT00467363
View directory record Official record
Conditions
Birth, Spontaneous Abortion
Interventions
acetylsalicylic-acid (aspirin), Folic acid
Drug · Dietary Supplement
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 40 Years · Female only
Enrollment
1,228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
4
States / cities
Denver, Colorado • Buffalo, New York • Scranton, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Sep 10, 2026, 3:34 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT)

NCT07224347
View directory record Official record
Conditions
Functional Disability, Dementia, Heart Disease, Stroke, Cancer, Bleeding, Depression, Frailty
Interventions
Not listed
Lead sponsor
Anne Murray
Other
Eligibility
65 Years and older
Enrollment
19,114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
22
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 10, 2026, 3:34 AM EDT
Terminated Phase 3 Interventional Results available

Aspirin for Treatment of Multiple Sclerosis-Related Fatigue

NCT00467584
View directory record Official record
Conditions
Multiple Sclerosis, Fatigue
Interventions
High Dose Aspirin (1300 mg/day), Low Dose Aspirin (162 mg/day), Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 10, 2026, 3:34 AM EDT